Increase in incidence of kidney cancer coupled with rise in the number of diagnostic procedures pertaining to it are the factors holding the responsibility of growth of the kidney cancer diagnostics market. Treatment of kidney cancer is based on grade and stage of tumor, and also the overall health and age.
The options include ablation, surgery, radiation therapy, immunotherapy, targeted drug therapy, and, at times, chemotherapy. Timely diagnosis of kidney cancer will help in resorting to any of these courses of treatment at the earliest.
The companies operating in the kidney cancer diagnostics market are investigating the new biomarkers for prognosis and diagnosis of kidney cancer, which would help in ameliorating the survival rate.
They are also exploring the therapeutic approaches, which could be targeting the extracellular vesicles (EVs) and using them as drug delivery system.
Kidney cancer develops when kidneys grow out of proportion. Those suffering from kidney cancer are likely to notice higher blood pressure, flank pain, blood in pee, and various other symptoms. Treatments of kidney cancer include chemotherapy, surgery, and radiation therapy.
Kidney cancer is common in individuals aged between 65 and 74. Types of kidney cancer include renal cell carcinoma (RCC), transitional cell cancer, renal sarcoma, and Wilms tumor.
The primary causes of kidney cancer are smoking, obesity, higher blood pressure, family history, radiation therapy, changes in genes (mutations), long-term dialysis treatment, tuberous sclerosis complex, or von Hippel-Lindau disease (VHL).
Increase in kidney diagnostics and therapeutics is supported by introduction of new products by the key players. For instance, in February 2021, Glenmark Pharma came up with SUTIB, a generic cancer treatment, in India. This oral multikinase inhibitor (MKI) is effective in treating those suffering from advanced renal cell carcinoma and gastrointestinal stromal tumors.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
As per Oxford Academic, there are 400,000 new-fangled cases of kidney cancer witnessed annually. It further states that the mortality rate worldwide is approaching 175,000 every year.
As per the National Institutes of Health, the five countries with the highest number of kidney cancer cases are China, the U.S., The Russian Federation, Germany, and Japan.
Funding for kidney cancer research has increased opportunities of developing a therapy for kidney cancer. For instance, in September 2022, the Department of Defense’s Kidney cancer Research Program sanctioned US$ 1 Mn as a grant for three years to Weill Cornell Medicine to help with research on role of protein ATF4 in the clear cell renal cell carcinoma (ccRCC).
In July 2022, Bristol-Myers Squibb announced results of its Phase III trial of Opdivo and Yervoy combination in renal cell carcinoma (RCC).
Need to combat kidney cancer diseases through therapeutics generated out of extensive research is thus catalyzing the kidney cancer diagnostics market growth.
Clear cell renal cell carcinoma, also called ccRCC, constitutes 2-6% of young adult and childhood cancer cases. As per the study published in Karger Journal in April 2022, higher BIRC5 expression is one of the key indicators of ccRCC prognosis, which, in turn, makes BIRC5 a good biomarker with regards to prediction of patient prognosis in ccRCC.
In August 2021, the researchers from the University of Pennsylvania’s Perelman School of Medicine discovered that health of specific tumors and cancer cells depends upon cholesterol and the receptor, along with demonstration that medication precisely targeting the receptor could render inability to the cancer cells to propagate and survive.
They further stated that future trials are bound to look into specific diets and medicines that could be used clinically for treating ccRCC. Conduction of continuous diagnostic procedures as mentioned above is thus promulgating the kidney cancer diagnostics market.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
As per the latest kidney cancer diagnostics market analysis, North America led the nephrocarcinoma diagnostics landscape in 2023 and the status quo is expected to remain unchanged during the forecast period.
This is attributed to spur in R&D expenditure by the pharmaceutical companies on the count of increase in geriatric population that is more prone to kidney cancer.
As per the Acute Coronary Syndrome (ACS) 2022 update, around 79,000 novel cases of kidney cancer were reported in the U.S. alone by the end of 2022. Moreover, according to the Canadian Cancer Society, around 8,000 Canadians were diagnosed with renal pelvis and kidney cancer in 2022.
Noticeable rise in the number of patients suffering from kidney cancer is thus expanding the kidney cancer diagnostics landscape.
The key players in the kidney cancer diagnostics market are launching new products to strengthen their position. For instance, in September 2021, MSN Labs launched Cabozantinib for treating renal cell carcinoma.
Siemens Healthineers, Koninklijke Philips N.V., FUJIFILM Holdings Corporation, Grail, Laboratory Corporation of America Holdings, Thermo Fisher Scientific, Myriad Genetics, Inc., Canon Medical Systems Corporation, QIAGEN N.V., Illumina, Inc., Ambry Genetics, Invitae Corp., and Centogene N.V. are some of the key players covered in the kidney cancer diagnostics market report.
These companies have been profiled based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2023 | US$ 3.6 Bn |
| Market Forecast (Value) in 2034 | US$ 6.9 Bn |
| Growth Rate (CAGR) | 6.2% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 3.6 Bn in 2023
It is projected to grow at a CAGR of 6.2% from 2024 to 2034
Growing prevalence of kidney cancer and increase in the frequency of diagnostic procedures for kidney cancer
Cancer research centers segment accounted for the largest share in 2023
North America was the dominant region in 2023
Siemens Healthineers, Koninklijke Philips N.V., FUJIFILM Holdings Corporation, Grail, Laboratory Corporation of America Holdings, Thermo Fisher Scientific, Myriad Genetics, Inc., Canon Medical Systems Corporation, QIAGEN N.V., Illumina, Inc., Ambry Genetics, Invitae Corp., and Centogene N.V.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Kidney Cancer Diagnostics Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Kidney Cancer Diagnostics Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by Product Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product Type, 2020-2034
6.3.1. Platform-based Products
6.3.2. Instrument-based Products
6.3.3. Kits and Reagents
6.3.4. Others (Consumables, etc.)
6.4. Market Attractiveness, by Product Type
7. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by Test Type
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Test Type, 2020-2034
7.3.1. Biopsy
7.3.2. Imaging Tests
7.3.3. Blood Tests
7.3.4. Others (Genetic Testing, etc.)
7.4. Market Attractiveness, by Test Type
8. Global Kidney Cancer Diagnostics Market Analysis and Forecast, By Cancer Stage
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, By Cancer Stage, 2020-2034
8.3.1. Stage 1
8.3.2. Stage 2
8.3.3. Stage 3
8.3.4. Stage 4
8.4. Market Attractiveness, By Cancer Stage
9. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by Tumor Type
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Tumor Type, 2020-2034
9.3.1. Renal Cell Carcinoma
9.3.2. Clear Cell Carcinoma
9.3.3. Non-clear Cell Carcinoma
9.4. Market Attractiveness, by Tumor Type
10. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by Technology
10.1. Introduction and Definitions
10.2. Key Findings/Developments
10.3. Market Value Forecast, by Tumor Type, 2020-2034
10.3.1. Fluorescent In Situ Hybridization
10.3.2. Next Generation Sequencing
10.3.3. Fluoroimmunoassay
10.3.4. Comparative Genomic Hybridization
10.3.5. Others (Immunohistochemical, etc.)
10.4. Market Attractiveness, by Tumor Type
11. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by End-user
11.1. Introduction and Definitions
11.2. Key Findings/Developments
11.3. Market Value Forecast, by End-user, 2020-2034
11.3.1. Hospitals
11.3.2. Cancer Research Centers
11.3.3. Oncology Clinics
11.3.4. Diagnostic Centers
11.3.5. Ambulatory Surgery Centers
11.3.6. Others (Research Institutes, etc.)
11.4. Market Attractiveness, by End-user
12. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by Region
12.1. Key Findings
12.2. Market Value Forecast, by Region, 2020-2034
12.2.1. North America
12.2.2. Europe
12.2.3. Asia Pacific
12.2.4. Latin America
12.2.5. Middle East & Africa
12.3. Market Attractiveness, by Region
13. North America Kidney Cancer Diagnostics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product Type, 2020-2034
13.2.1. Platform-based Products
13.2.2. Instrument-based Products
13.2.3. Kits and Reagents
13.2.4. Others (Consumables, etc.)
13.3. Market Attractiveness, by Product Type
13.4. Market Value Forecast, by Test Type, 2020-2034
13.4.1. Biopsy
13.4.2. Imaging Tests
13.4.3. Blood Tests
13.4.4. Others (Genetic Testing, etc.)
13.5. Market Attractiveness, by Test Type
13.6. Market Value Forecast, By Cancer Stage, 2020-2034
13.6.1. Stage 1
13.6.2. Stage 2
13.6.3. Stage 3
13.6.4. Stage 4
13.7. Market Attractiveness, By Cancer Stage
13.8. Market Value Forecast, by Tumor Type, 2020-2034
13.8.1. Renal Cell Carcinoma
13.8.2. Clear Cell Carcinoma
13.8.3. Non-clear Cell Carcinoma
13.9. Market Attractiveness, by Tumor Type
13.10. Market Value Forecast, by Technology 2020-2034
13.10.1. Fluorescent In Situ Hybridization
13.10.2. Next Generation Sequencing
13.10.3. Fluoroimmunoassay
13.10.4. Comparative Genomic Hybridization
13.10.5. Others (Immunohistochemical, etc.)
13.11. Market Attractiveness, by Technology
13.12. Market Value Forecast, by End-user, 2020-2034
13.12.1. Hospitals
13.12.2. Cancer Research Centers
13.12.3. Oncology Clinics
13.12.4. Diagnostic Centers
13.12.5. Ambulatory Surgery Centers
13.12.6. Others (Research Institutes, etc.)
13.13. Market Attractiveness, by End-user
13.14. Market Value Forecast, by Country/Sub-region, 2020-2034
13.14.1. U.S.
13.14.2. Canada
13.15. Market Attractiveness Analysis
13.15.1. By Product Type
13.15.2. By Test Type
13.15.3. By Cancer Stage
13.15.4. By Tumor Type
13.15.5. By End-user
13.15.6. By Country
14. Europe Kidney Cancer Diagnostics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product Type, 2020-2034
14.2.1. Platform-based Products
14.2.2. Instrument-based Products
14.2.3. Kits and Reagents
14.2.4. Others (Consumables, etc.)
14.3. Market Attractiveness, by Product Type
14.4. Market Value Forecast, by Test Type, 2020-2034
14.4.1. Biopsy
14.4.2. Imaging Tests
14.4.3. Blood Tests
14.4.4. Others (Genetic Testing, etc.)
14.5. Market Attractiveness, by Test Type
14.6. Market Value Forecast, By Cancer Stage, 2020-2034
14.6.1. Stage 1
14.6.2. Stage 2
14.6.3. Stage 3
14.6.4. Stage 4
14.7. Market Attractiveness, By Cancer Stage
14.8. Market Value Forecast, by Tumor Type, 2020-2034
14.8.1. Renal Cell Carcinoma
14.8.2. Clear Cell Carcinoma
14.8.3. Non-clear Cell Carcinoma
14.9. Market Attractiveness, by Tumor Type
14.10. Market Value Forecast, by Technology, 2020-2034
14.10.1. Fluorescent In Situ Hybridization
14.10.2. Next Generation Sequencing
14.10.3. Fluoroimmunoassay
14.10.4. Comparative Genomic Hybridization
14.10.5. Others (Immunohistochemical, etc.)
14.11. Market Attractiveness, by Technology
14.12. Market Value Forecast, by End-user, 2020-2034
14.12.1. Hospitals
14.12.2. Cancer Research Centers
14.12.3. Oncology Clinics
14.12.4. Diagnostic Centers
14.12.5. Ambulatory Surgery Centers
14.12.6. Others (Research Institutes, etc.)
14.13. Market Attractiveness, by End-user
14.14. Market Value Forecast, by Country/Sub-region, 2020-2034
14.14.1. Germany
14.14.2. U.K.
14.14.3. France
14.14.4. Italy
14.14.5. Spain
14.14.6. Rest of Europe
14.15. Market Attractiveness Analysis
14.15.1. By Product Type
14.15.2. By Test Type
14.15.3. By Cancer Stage
14.15.4. By Tumor Type
14.15.5. By End-user
14.15.6. By Country/Sub-region
15. Asia Pacific Kidney Cancer Diagnostics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Product Type, 2020-2034
15.2.1. Platform-based Products
15.2.2. Instrument-based Products
15.2.3. Kits and Reagents
15.2.4. Others (Consumables, etc.)
15.3. Market Attractiveness, by Product Type
15.4. Market Value Forecast, by Test Type, 2020-2034
15.4.1. Biopsy
15.4.2. Imaging Tests
15.4.3. Blood Tests
15.4.4. Others (Genetic Testing, etc.)
15.5. Market Attractiveness, by Test Type
15.6. Market Value Forecast, By Cancer Stage, 2020-2034
15.6.1. Stage 1
15.6.2. Stage 2
15.6.3. Stage 3
15.6.4. Stage 4
15.7. Market Attractiveness, By Cancer Stage
15.8. Market Value Forecast, by Tumor Type, 2020-2034
15.8.1. Renal Cell Carcinoma
15.8.2. Clear Cell Carcinoma
15.8.3. Non-clear Cell Carcinoma
15.9. Market Attractiveness, by Tumor Type
15.10. Market Value Forecast, by Technology 2020-2034
15.10.1. Fluorescent In Situ Hybridization
15.10.2. Next Generation Sequencing
15.10.3. Fluoroimmunoassay
15.10.4. Comparative Genomic Hybridization
15.10.5. Others (Immunohistochemical, etc.)
15.11. Market Attractiveness, by Technology
15.12. Market Value Forecast, by End-user, 2020-2034
15.12.1. Hospitals
15.12.2. Cancer Research Centers
15.12.3. Oncology Clinics
15.12.4. Diagnostic Centers
15.12.5. Ambulatory Surgery Centers
15.12.6. Others (Research Institutes, etc.)
15.13. Market Attractiveness, by End-user
15.14. Market Value Forecast, by Country/Sub-region, 2020-2034
15.14.1. China
15.14.2. Japan
15.14.3. India
15.14.4. Australia & New Zealand
15.14.5. Rest of Asia Pacific
15.15. Market Attractiveness Analysis
15.15.1. By Product Type
15.15.2. By Test Type
15.15.3. By Cancer Stage
15.15.4. By Tumor Type
15.15.5. By End-user
15.15.6. By Country/Sub-region
16. Latin America Kidney Cancer Diagnostics Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Product Type, 2020-2034
16.2.1. Platform-based Products
16.2.2. Instrument-based Products
16.2.3. Kits and Reagents
16.2.4. Others (Consumables, etc.)
16.3. Market Attractiveness, by Product Type
16.4. Market Value Forecast, by Test Type, 2020-2034
16.4.1. Biopsy
16.4.2. Imaging Tests
16.4.3. Blood Tests
16.4.4. Others (Genetic Testing, etc.)
16.5. Market Attractiveness, by Test Type
16.6. Market Value Forecast, By Cancer Stage, 2020-2034
16.6.1. Stage 1
16.6.2. Stage 2
16.6.3. Stage 3
16.6.4. Stage 4
16.7. Market Attractiveness, By Cancer Stage
16.8. Market Value Forecast, by Tumor Type, 2020-2034
16.8.1. Renal Cell Carcinoma
16.8.2. Clear Cell Carcinoma
16.8.3. Non-clear Cell Carcinoma
16.9. Market Attractiveness, by Tumor Type
16.10. Market Value Forecast, by Technology, 2020-2034
16.10.1. Fluorescent In Situ Hybridization
16.10.2. Next Generation Sequencing
16.10.3. Fluoroimmunoassay
16.10.4. Comparative Genomic Hybridization
16.10.5. Others (Immunohistochemical, etc.)
16.11. Market Attractiveness, by Technology
16.12. Market Value Forecast, by End-user, 2020-2034
16.12.1. Hospitals
16.12.2. Cancer Research Centers
16.12.3. Oncology Clinics
16.12.4. Diagnostic Centers
16.12.5. Ambulatory Surgery Centers
16.12.6. Others (Research Institutes, etc.)
16.13. Market Attractiveness, by End-user
16.14. Market Value Forecast, by Country/Sub-region, 2020-2034
16.14.1. Brazil
16.14.2. Mexico
16.14.3. Rest of Latin America
16.15. Market Attractiveness Analysis
16.15.1. By Product Type
16.15.2. By Test Type
16.15.3. By Cancer Stage
16.15.4. By Tumor Type
16.15.5. By End-user
16.15.6. By Country/Sub-region
17. Middle East & Africa Kidney Cancer Diagnostics Market Analysis and Forecast
17.1. Introduction
17.1.1. Key Findings
17.2. Market Value Forecast, by Product Type, 2020-2034
17.2.1. Platform-based Products
17.2.2. Instrument-based Products
17.2.3. Kits and Reagents
17.2.4. Others (Consumables, etc.)
17.3. Market Attractiveness, by Product Type
17.4. Market Value Forecast, by Test Type, 2020-2034
17.4.1. Biopsy
17.4.2. Imaging Tests
17.4.3. Blood Tests
17.4.4. Others (Genetic Testing, etc.)
17.5. Market Attractiveness, by Test Type
17.6. Market Value Forecast, By Cancer Stage, 2020-2034
17.6.1. Stage 1
17.6.2. Stage 2
17.6.3. Stage 3
17.6.4. Stage 4
17.7. Market Attractiveness, By Cancer Stage
17.8. Market Value Forecast, by Tumor Type, 2020-2034
17.8.1. Renal Cell Carcinoma
17.8.2. Clear Cell Carcinoma
17.8.3. Non-clear Cell Carcinoma
17.9. Market Attractiveness, by Tumor Type
17.10. Market Value Forecast, by Technology, 2020-2034
17.10.1. Fluorescent In Situ Hybridization
17.10.2. Next Generation Sequencing
17.10.3. Fluoroimmunoassay
17.10.4. Comparative Genomic Hybridization
17.10.5. Others (Immunohistochemical, etc.)
17.11. Market Attractiveness, by Technology
17.12. Market Value Forecast, by End-user, 2020-2034
17.12.1. Hospitals
17.12.2. Ambulatory Surgical Centers
17.12.3. Nursing Centers
17.12.4. Others (Long Term Care Centers, etc.)
17.13. Market Attractiveness, by End-user
17.14. Market Value Forecast, by Country/Sub-region, 2020-2034
17.14.1. GCC Countries
17.14.2. South Africa
17.14.3. Rest of Middle East & Africa
17.15. Market Attractiveness Analysis
17.15.1. By Product Type
17.15.2. By Test Type
17.15.3. By Cancer Stage
17.15.4. By Tumor Type
17.15.5. By End-user
17.15.6. By Country/Sub-region
18. Competition Landscape
18.1. Market Player - Competition Matrix (By Tier and Size of Companies)
18.2. Market Share Analysis, by Company (2023)
18.3. Company Profiles
18.3.1. Siemens Healthineers
18.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.1.2. Product Portfolio
18.3.1.3. Financial Overview
18.3.1.4. SWOT Analysis
18.3.1.5. Strategic Overview
18.3.2. Koninklijke Philips N.V.
18.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.2.2. Product Portfolio
18.3.2.3. Financial Overview
18.3.2.4. SWOT Analysis
18.3.2.5. Strategic Overview
18.3.3. FUJIFILM Holdings Corporation
18.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.3.2. Product Portfolio
18.3.3.3. Financial Overview
18.3.3.4. SWOT Analysis
18.3.3.5. Strategic Overview
18.3.4. Grail
18.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.4.2. Product Portfolio
18.3.4.3. Financial Overview
18.3.4.4. SWOT Analysis
18.3.4.5. Strategic Overview
18.3.5. Laboratory Corporation of America Holdings
18.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.5.2. Product Portfolio
18.3.5.3. Financial Overview
18.3.5.4. SWOT Analysis
18.3.6. Thermo Fisher Scientific
18.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.6.2. Product Portfolio
18.3.6.3. Financial Overview
18.3.6.4. SWOT Analysis
18.3.6.5. Strategic Overview
18.3.7. Myriad Genetics, Inc.
18.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.7.2. Product Portfolio
18.3.7.3. Financial Overview
18.3.7.4. SWOT Analysis
18.3.7.5. Strategic Overview
18.3.8. Canon Medical Systems Corporation
18.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.8.2. Product Portfolio
18.3.8.3. Financial Overview
18.3.8.4. SWOT Analysis
18.3.8.5. Strategic Overview
18.3.9. QIAGEN N.V.
18.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.9.2. Product Portfolio
18.3.9.3. Financial Overview
18.3.9.4. SWOT Analysis
18.3.9.5. Strategic Overview
18.3.10. Illumina, Inc.
18.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.10.2. Product Portfolio
18.3.10.3. Financial Overview
18.3.10.4. SWOT Analysis
18.3.10.5. Strategic Overview
18.3.11. Ambry Genetics
18.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.11.2. Product Portfolio
18.3.11.3. Financial Overview
18.3.11.4. SWOT Analysis
18.3.11.5. Strategic Overview
18.3.12. Invitae Corp.
18.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.12.2. Product Portfolio
18.3.12.3. Financial Overview
18.3.12.4. SWOT Analysis
18.3.12.5. Strategic Overview
18.3.13. Centogene N.V.
18.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.13.2. Product Portfolio
18.3.13.3. Financial Overview
18.3.13.4. SWOT Analysis
18.3.13.5. Strategic Overview
List of Tables
Table 01: Global Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Product Type, 2020-2034
Table 02: Global Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Test Type, 2020-2034
Table 03: Global Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Tumor Type, 2020-2034
Table 04: Global Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, By Cancer Stage, 2020-2034
Table 05: Global Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, By Technology, 2020-2034
Table 06: Global Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 07: Global Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Region, 2020-2034
Table 08: North America Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Country, 2020-2034
Table 09: North America Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Product Type, 2020-2034
Table 10: North America Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Test Type, 2020-2034
Table 11: North America Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, By Cancer Stage, 2020-2034
Table 12: North America Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Tumor Type, 2020-2034
Table 13: North America Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Technology, 2020-2034
Table 14: North America Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 15: Europe Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 16: Europe Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Product Type, 2020-2034
Table 17: Europe Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Test Type, 2020-2034
Table 18: Europe Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, By Cancer Stage, 2020-2034
Table 19: Europe Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Tumor Type, 2020-2034
Table 20: Europe Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Technology, 2020-2034
Table 21: Europe Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 22: Asia Pacific Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 23: Asia Pacific Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Product Type, 2020-2034
Table 24: Asia Pacific Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Test Type, 2020-2034
Table 25: Asia Pacific Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, By Cancer Stage, 2020-2034
Table 26: Asia Pacific Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Tumor Type, 2020-2034
Table 27: Asia Pacific Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Technology, 2020-2034
Table 28: Asia Pacific Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 29: Latin America Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 30: Latin America Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Product Type, 2020-2034
Table 31: Latin America Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Test Type, 2020-2034
Table 32: Latin America Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, By Cancer Stage, 2020-2034
Table 33: Latin America Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Tumor Type, 2020-2034
Table 34: Latin America Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Technology, 2020-2034
Table 35: Latin America Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 36: Middle East & Africa Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 37: Middle East & Africa Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Product Type, 2020-2034
Table 38: Middle East & Africa Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Test Type, 2020-2034
Table 39: Middle East & Africa Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, By Cancer Stage, 2020-2034
Table 40: Middle East & Africa Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Tumor Type, 2020-2034
Table 41: Middle East & Africa Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Technology, 2020-2034
Table 42: Middle East & Africa Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by End-user, 2020-2034
List of Figures
Figure 01: Global Kidney Cancer Diagnostics Market Size (US$ Bn) and Distribution (%), by Region, 2023 and 2034
Figure 02: Global Kidney Cancer Diagnostics Market Revenue (US$ Bn), by Product Type, 2023
Figure 03: Global Kidney Cancer Diagnostics Market Value Share, by Product Type, 2023
Figure 04: Global Kidney Cancer Diagnostics Market Revenue (US$ Bn), by Test Type, 2023
Figure 05: Global Kidney Cancer Diagnostics Market Value Share, by Test Type, 2023
Figure 06: Global Kidney Cancer Diagnostics Market Revenue (US$ Bn), By Cancer Stage, 2023
Figure 07: Global Kidney Cancer Diagnostics Market Value Share, By Cancer Stage, 2023
Figure 08: Global Kidney Cancer Diagnostics Market Revenue (US$ Bn), by Tumor Type, 2023
Figure 09: Global Kidney Cancer Diagnostics Market Value Share, by Tumor Type, 2023
Figure 10: Global Kidney Cancer Diagnostics Market Revenue (US$ Bn), by Technology, 2023
Figure 11: Global Kidney Cancer Diagnostics Market Value Share, by Technology, 2023
Figure 12: Global Kidney Cancer Diagnostics Market Revenue (US$ Bn), by End-user, 2023
Figure 13: Global Kidney Cancer Diagnostics Market Value Share, by End-user, 2023
Figure 14: Global Kidney Cancer Diagnostics Market Value Share, by Region, 2023
Figure 15: Global Kidney Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020-2034
Figure 16: Global Kidney Cancer Diagnostics Market Value Share Analysis, by Product Type, 2023 and 2034
Figure 17: Global Kidney Cancer Diagnostics Market Attractiveness Analysis, by Product Type, 2024-2034
Figure 18: Global Kidney Cancer Diagnostics Market Value Share Analysis, by Test Type, 2023 and 2034
Figure 19: Global Kidney Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2024-2034
Figure 20: Global Kidney Cancer Diagnostics Market Value Share Analysis, By Cancer Stage, 2023 and 2034
Figure 21: Global Kidney Cancer Diagnostics Market Attractiveness Analysis, By Cancer Stage, 2024-2034
Figure 22: Global Kidney Cancer Diagnostics Market Revenue (US$ Bn), by Tumor Type, 2023
Figure 23: Global Kidney Cancer Diagnostics Market Value Share, by Tumor Type, 2023
Figure 24: Global Kidney Cancer Diagnostics Market Revenue (US$ Bn), by Technology, 2023
Figure 25: Global Kidney Cancer Diagnostics Market Value Share, by Technology, 2023
Figure 26: Global Kidney Cancer Diagnostics Market Revenue (US$ Bn), by End-user, 2023
Figure 27: Global Kidney Cancer Diagnostics Market Value Share, by End-user, 2023
Figure 28: Global Kidney Cancer Diagnostics Market Value Share Analysis, by Region, 2023 and 2034
Figure 29: Global Kidney Cancer Diagnostics Market Attractiveness Analysis, by Region, 2024-2034
Figure 30: North America Kidney Cancer Diagnostics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 31: North America Kidney Cancer Diagnostics Market Attractiveness Analysis, by Country, 2024-2034
Figure 32: North America Kidney Cancer Diagnostics Market Value Share Analysis, by Country, 2023 and 2034
Figure 33: North America Kidney Cancer Diagnostics Market Value Share Analysis, by Product Type, 2023 and 2034
Figure 34: North America Kidney Cancer Diagnostics Market Value Share Analysis, by Test Type, 2023 and 2034
Figure 35: North America Kidney Cancer Diagnostics Market Value Share Analysis, By Cancer Stage, 2023 and 2034
Figure 36: North America Kidney Cancer Diagnostics Market Value Share Analysis, by Tumor Type, 2023 and 2034
Figure 37: North America Kidney Cancer Diagnostics Market Value Share Analysis, by Technology, 2023 and 2034
Figure 38: North America Kidney Cancer Diagnostics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 39: North America Kidney Cancer Diagnostics Market Attractiveness Analysis, by Product Type, 2024-2034
Figure 40: North America Kidney Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2024-2034
Figure 41: North America Kidney Cancer Diagnostics Market Attractiveness Analysis, By Cancer Stage, 2023-2034
Figure 42: North America Kidney Cancer Diagnostics Market Attractiveness Analysis, by Tumor Type, 2024-2034
Figure 43: North America Kidney Cancer Diagnostics Market Attractiveness Analysis, by Technology, 2024-2034
Figure 44: North America Kidney Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2024-2034
Figure 45: Europe Kidney Cancer Diagnostics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 46: Europe Kidney Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 47: Europe Kidney Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 48: Europe Kidney Cancer Diagnostics Market Value Share Analysis, by Product Type, 2023 and 2034
Figure 49: Europe Kidney Cancer Diagnostics Market Value Share Analysis, by Test Type, 2023 and 2034
Figure 50: Europe Kidney Cancer Diagnostics Market Value Share Analysis, By Cancer Stage, 2023 and 2034
Figure 51: Europe Kidney Cancer Diagnostics Market Value Share Analysis, by Tumor Type, 2023 and 2034
Figure 52: North America Kidney Cancer Diagnostics Market Attractiveness Analysis, by Technology, 2024-2034
Figure 53: Europe Kidney Cancer Diagnostics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 54: Europe Kidney Cancer Diagnostics Market Attractiveness Analysis, by Product Type, 2024-2034
Figure 55: Europe Kidney Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2024-2034
Figure 56: Europe Kidney Cancer Diagnostics Market Attractiveness Analysis, By Cancer Stage, 2024-2034
Figure 57: Europe Kidney Cancer Diagnostics Market Attractiveness Analysis, by Tumor Type, 2024-2034
Figure 58: Europe Kidney Cancer Diagnostics Market Attractiveness Analysis, by Technology, 2024-2034
Figure 59: Europe Kidney Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2024-2034
Figure 60: Asia Pacific Kidney Cancer Diagnostics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 61: Asia Pacific Kidney Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 62: Asia Pacific Kidney Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 63: Asia Pacific Kidney Cancer Diagnostics Market Value Share Analysis, by Product Type, 2023 and 2034
Figure 64: Asia Pacific Kidney Cancer Diagnostics Market Value Share Analysis, by Test Type, 2023 and 2034
Figure 65: Asia Pacific Kidney Cancer Diagnostics Market Value Share Analysis, By Cancer Stage, 2023 and 2034
Figure 66: Asia Pacific Kidney Cancer Diagnostics Market Value Share Analysis, by Tumor Type, 2023 and 2034
Figure 67: Asia Pacific Kidney Cancer Diagnostics Market Value Share Analysis, by Technology, 2023 and 2034
Figure 68: Asia Pacific Kidney Cancer Diagnostics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 69: Asia Pacific Kidney Cancer Diagnostics Market Attractiveness Analysis, by Product Type, 2024-2034
Figure 70: Asia Pacific Kidney Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2024-2034
Figure 71: Asia Pacific Kidney Cancer Diagnostics Market Attractiveness Analysis, By Cancer Stage, 2024-2034
Figure 72: Asia Pacific Kidney Cancer Diagnostics Market Attractiveness Analysis, by Tumor Type, 2024-2034
Figure 73: Asia Pacific Kidney Cancer Diagnostics Market Attractiveness Analysis, by Technology, 2024-2034
Figure 74: Asia Pacific Kidney Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2024-2034
Figure 75: Latin America Kidney Cancer Diagnostics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 76: Latin America Kidney Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 77: Latin America Kidney Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 78: Latin America Kidney Cancer Diagnostics Market Value Share Analysis, by Product Type, 2023 and 2034
Figure 79: Latin America Kidney Cancer Diagnostics Market Value Share Analysis, by Test Type, 2023 and 2034
Figure 80: Latin America Kidney Cancer Diagnostics Market Value Share Analysis, By Cancer Stage, 2023 and 2034
Figure 81: Latin America Kidney Cancer Diagnostics Market Value Share Analysis, by Tumor Type, 2023 and 2034
Figure 82: Latin America Kidney Cancer Diagnostics Market Value Share Analysis, by Technology, 2023 and 2034
Figure 83: Latin America Kidney Cancer Diagnostics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 84: Latin America Kidney Cancer Diagnostics Market Attractiveness Analysis, by Product Type, 2024-2034
Figure 85: Latin America Kidney Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2024-2034
Figure 86: Latin America Kidney Cancer Diagnostics Market Attractiveness Analysis, By Cancer Stage, 2023-2034
Figure 87: Latin America Kidney Cancer Diagnostics Market Attractiveness Analysis, by Tumor Type, 2024-2034
Figure 88: Latin America Kidney Cancer Diagnostics Market Attractiveness Analysis, by Technology, 2024-2034
Figure 89: Latin America Kidney Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2024-2034
Figure 90: Middle East & Africa Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 91: Middle East & Africa Kidney Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 92: Middle East & Africa Kidney Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 93: Middle East & Africa Kidney Cancer Diagnostics Market Value Share Analysis, by Product Type, 2023 and 2034
Figure 94: Middle East & Africa Kidney Cancer Diagnostics Market Value Share Analysis, by Test Type, 2023 and 2034
Figure 95: Middle East & Africa Kidney Cancer Diagnostics Market Value Share Analysis, By Cancer Stage, 2023 and 2034
Figure 96: Middle East & Africa Kidney Cancer Diagnostics Market Value Share Analysis, by Tumor Type, 2023 and 2034
Figure 97: Middle East & Africa Kidney Cancer Diagnostics Market Value Share Analysis, by Technology, 2023 and 2034
Figure 98: Middle East & Africa Kidney Cancer Diagnostics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 99: Middle East & Africa Kidney Cancer Diagnostics Market Attractiveness Analysis, by Product Type, 2024-2034
Figure 100: Middle East & Africa Kidney Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2024-2034
Figure 101: Middle East & Africa Kidney Cancer Diagnostics Market Attractiveness Analysis, By Cancer Stage, 2023-2034
Figure 102: Middle East & Africa Kidney Cancer Diagnostics Market Attractiveness Analysis, by Tumor Type, 2024-2034
Figure 103: Middle East & Africa Kidney Cancer Diagnostics Market Attractiveness Analysis, by Technology, 2024-2034
Figure 104: Middle East & Africa Kidney Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Kidney Cancer Diagnostics Market
